Biotechnology News

SAN FRANCISCO, Oct. 23, 2019 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN), today announced the dosing of the first patient in the LAPIS Phase 3 clinical study of pamrevlumab in patients with...

Initial data with AXO-AAV-GM2 suggests stabilization of disease course, attainment of normal developmental milestones, and improvement in myelination on brain MRIAXO-AAV-GM2 generally safe and...

BOSTON, Oct. 23, 2019 (GLOBE NEWSWIRE) -- Akcea Therapeutics, Inc. (NASDAQ: AKCA), a majority-owned affiliate of Ionis Pharmaceuticals, Inc., announced today that the company has promoted Kyle Jenne...

LA JOLLA, Calif., Oct. 23, 2019 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the JASDAQ Market of the Tokyo Stock...

UPPSALA, SWEDEN. LIDDS AB (publ) – Data from a voluntary open label extension (OLE) study indicates longer PSA effect with Liproca® Depot in prostate cancer patients than anticipated. In half of the...

Læs venligst hele meddelesen i den vedhæftede PDF Vedhæftet fil 2019_44_Q32019_CompanyAnnouncement_DK_FINAL ...

Please read the announcement in the attached PDF Attachment 2019_44_Q32019_CompanyAnnouncement_EN_FINAL ...

聖地牙哥, Oct. 23, 2019 (GLOBE NEWSWIRE) -- Crown Bioscience 今天宣佈推出全新的腫瘤類器官藥物開發平台，此平台有潛力大幅地提升臨床前藥物發現的預測性和速度。 推行平台的初步階段涉及第一個商用 3D  體外  PDX 來源類器官 (PDXO) 模型，此模型由 CrownBio 獨家擁有的超過 2500 個患者來源異種移植 (PDX)...

圣迭戈, Oct. 23, 2019 (GLOBE NEWSWIRE) -- Crown Bioscience今天宣布推出一个新的肿瘤类器官药物开发平台，有望显著提高临床前药物研发的预测性和速度。 该平台的初始阶段提供了首个市场有售的三维体外PDX源性类器官（PDXO）模型，由CrownBio超过2500多个人源肿瘤异体移植（PDX）模型组成的独特特征模型库所生成。 ...

本資料は、Crown Bioscience Inc.が 2019 年 10月 17 日に発表しましたプレスリリースの和文抄訳であり、内容につきましては英語原文が優先されます。 サンディエゴ発, Oct. 23, 2019 (GLOBE NEWSWIRE) -- Crown Bioscience...